Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy

BackgroundModulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment.M...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal for immunotherapy of cancer Ročník 9; číslo 9; s. e003311
Hlavní autori:	Pinato, David J., Murray, Sam M, Forner, Alejandro, Kaneko, Takahiro, Fessas, Petros, Toniutto, Pierluigi, Mínguez, Beatriz, Cacciato, Valentina, Avellini, Claudio, Diaz, Alba, Boyton, Rosemary J., Altmann, Daniel M., Goldin, Robert D, Akarca, Ayse U, Marafioti, Teresa, Mauri, Francesco A, Casagrande, Edoardo, Grillo, Federica, Giannini, Edoardo, Bhoori, Sherrie, Mazzaferro, Vincenzo
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England BMJ Publishing Group Ltd 01.09.2021 BMJ Publishing Group LTD BMJ Publishing Group
Edícia:	Original research
Predmet:	Adult Aged Apoptosis Cancer Cancer therapies Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Cell death Chemoembolization Chemoembolization, Therapeutic - methods Chemotherapy Clinical trials Clinical/Translational Cancer Immunotherapy Cytotoxicity Embolization Female Gene expression Humans Immunogenic Cell Death - drug effects Immunotherapy Immunotherapy - methods Ligands Liver cancer liver neoplasms Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Middle Aged Patients Surgery Tumors United Kingdom > UK New York United States > US liver neoplasms immunotherapy
ISSN:	2051-1426, 2051-1426
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	BackgroundModulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment.MethodsWe profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T− (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), Lag-3, Tim-3 and CD163.ResultsWe analyzed 119 patients resected (n=25, 21%) or transplanted (n=94, 79%) for Child-Pugh A (n=65, 55%) and Barcelona Clinic Liver Cancer stage A (n=92, 77%) hepatocellular carcinoma. T+ samples displayed lower IT CD4+/FOXP3+ (p=0.006), CD8+ (p=0.002) and CD8+/PD-1+ and NT CD8+/PD-1+ (p<0.001) compared with T−. Lower IT (p=0.005) and NT CD4+/FOXP3+ (p=0.03) predicted for improved recurrence-free survival. In a subset of samples (n=24), transcriptomic analysis revealed upregulation of a pro-inflammatory response in T+. T+ samples were enriched for IRF2 expression (p=0.01), an interferon-regulated transcription factor implicated in cancer immune-evasion. T-cell clonality and expression of PD-L1, IDO-1, CTLA-4, Lag-3, Tim-3 and CD163 was similar in T+ versus T−.ConclusionsTACE is associated with lower IT density of immune-exhausted effector cytotoxic and T-regs, with significant upregulation of pro-inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and strengthens the rationale for developing immunotherapy alongside TACE.
AbstractList	BackgroundModulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment.MethodsWe profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T− (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), Lag-3, Tim-3 and CD163.ResultsWe analyzed 119 patients resected (n=25, 21%) or transplanted (n=94, 79%) for Child-Pugh A (n=65, 55%) and Barcelona Clinic Liver Cancer stage A (n=92, 77%) hepatocellular carcinoma. T+ samples displayed lower IT CD4+/FOXP3+ (p=0.006), CD8+ (p=0.002) and CD8+/PD-1+ and NT CD8+/PD-1+ (p<0.001) compared with T−. Lower IT (p=0.005) and NT CD4+/FOXP3+ (p=0.03) predicted for improved recurrence-free survival. In a subset of samples (n=24), transcriptomic analysis revealed upregulation of a pro-inflammatory response in T+. T+ samples were enriched for IRF2 expression (p=0.01), an interferon-regulated transcription factor implicated in cancer immune-evasion. T-cell clonality and expression of PD-L1, IDO-1, CTLA-4, Lag-3, Tim-3 and CD163 was similar in T+ versus T−.ConclusionsTACE is associated with lower IT density of immune-exhausted effector cytotoxic and T-regs, with significant upregulation of pro-inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and strengthens the rationale for developing immunotherapy alongside TACE. Modulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment. We profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T- (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), Lag-3, Tim-3 and CD163. We analyzed 119 patients resected (n=25, 21%) or transplanted (n=94, 79%) for Child-Pugh A (n=65, 55%) and Barcelona Clinic Liver Cancer stage A (n=92, 77%) hepatocellular carcinoma. T+ samples displayed lower IT CD4+/FOXP3+ (p=0.006), CD8+ (p=0.002) and CD8+/PD-1+ and NT CD8+/PD-1+ (p<0.001) compared with T-. Lower IT (p=0.005) and NT CD4+/FOXP3+ (p=0.03) predicted for improved recurrence-free survival. In a subset of samples (n=24), transcriptomic analysis revealed upregulation of a pro-inflammatory response in T+. T+ samples were enriched for IRF2 expression (p=0.01), an interferon-regulated transcription factor implicated in cancer immune-evasion. T-cell clonality and expression of PD-L1, IDO-1, CTLA-4, Lag-3, Tim-3 and CD163 was similar in T+ versus T-. TACE is associated with lower IT density of immune-exhausted effector cytotoxic and T-regs, with significant upregulation of pro-inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and strengthens the rationale for developing immunotherapy alongside TACE. Modulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment.BACKGROUNDModulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment.We profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T- (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), Lag-3, Tim-3 and CD163.METHODSWe profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T- (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), Lag-3, Tim-3 and CD163.We analyzed 119 patients resected (n=25, 21%) or transplanted (n=94, 79%) for Child-Pugh A (n=65, 55%) and Barcelona Clinic Liver Cancer stage A (n=92, 77%) hepatocellular carcinoma. T+ samples displayed lower IT CD4+/FOXP3+ (p=0.006), CD8+ (p=0.002) and CD8+/PD-1+ and NT CD8+/PD-1+ (p<0.001) compared with T-. Lower IT (p=0.005) and NT CD4+/FOXP3+ (p=0.03) predicted for improved recurrence-free survival. In a subset of samples (n=24), transcriptomic analysis revealed upregulation of a pro-inflammatory response in T+. T+ samples were enriched for IRF2 expression (p=0.01), an interferon-regulated transcription factor implicated in cancer immune-evasion. T-cell clonality and expression of PD-L1, IDO-1, CTLA-4, Lag-3, Tim-3 and CD163 was similar in T+ versus T-.RESULTSWe analyzed 119 patients resected (n=25, 21%) or transplanted (n=94, 79%) for Child-Pugh A (n=65, 55%) and Barcelona Clinic Liver Cancer stage A (n=92, 77%) hepatocellular carcinoma. T+ samples displayed lower IT CD4+/FOXP3+ (p=0.006), CD8+ (p=0.002) and CD8+/PD-1+ and NT CD8+/PD-1+ (p<0.001) compared with T-. Lower IT (p=0.005) and NT CD4+/FOXP3+ (p=0.03) predicted for improved recurrence-free survival. In a subset of samples (n=24), transcriptomic analysis revealed upregulation of a pro-inflammatory response in T+. T+ samples were enriched for IRF2 expression (p=0.01), an interferon-regulated transcription factor implicated in cancer immune-evasion. T-cell clonality and expression of PD-L1, IDO-1, CTLA-4, Lag-3, Tim-3 and CD163 was similar in T+ versus T-.TACE is associated with lower IT density of immune-exhausted effector cytotoxic and T-regs, with significant upregulation of pro-inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and strengthens the rationale for developing immunotherapy alongside TACE.CONCLUSIONSTACE is associated with lower IT density of immune-exhausted effector cytotoxic and T-regs, with significant upregulation of pro-inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and strengthens the rationale for developing immunotherapy alongside TACE.
Author	Forner, Alejandro Giannini, Edoardo Marafioti, Teresa Mazzaferro, Vincenzo Goldin, Robert D Diaz, Alba Fessas, Petros Altmann, Daniel M. Boyton, Rosemary J. Avellini, Claudio Toniutto, Pierluigi Pinato, David J. Mínguez, Beatriz Murray, Sam M Kaneko, Takahiro Akarca, Ayse U Mauri, Francesco A Bhoori, Sherrie Grillo, Federica Cacciato, Valentina Casagrande, Edoardo
AuthorAffiliation	14 Department of Surgery and Cancer , Imperial College London , London , UK 3 Department of Infectious Diseases, Faculty of Medicine , Imperial College London, Hammersmith Hospital Campus , London , UK 11 Pathology Department, Barcelona Clinic Liver Cancer (BCLC) Group, Hospital Clínic , University of Barcelona , Barcelona , Spain 8 Liver Unit, Hospital Universitari Vall d’Hebron , Universitat Autonoma de Barcelona , Barcelona , Spain 16 Department of Oncology , University of Milan , Milano , Italy 10 Institute of Histopathology , Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" , Udine , Italy 13 Department of Histopathology , University College London Cancer Institute , London , UK 15 Department of Surgical Sciences , IRCCS-Ospedale Policlinico San Martino , Genoa , Italy 1 Department of Surgery & Cancer, Faculty of Medicine , Imperial College London, Hammersmith Hospital Campus , London , UK 7 Hepatology and Liver Transplantation Unit, Department of Medical Area (DAME) , Un
AuthorAffiliation_xml	– name: 7 Hepatology and Liver Transplantation Unit, Department of Medical Area (DAME) , University of Udine , Udine , Italy – name: 15 Department of Surgical Sciences , IRCCS-Ospedale Policlinico San Martino , Genoa , Italy – name: 2 Division of Oncology, Department of Translational Medicine , Universita del Piemonte Orientale "A. Avogadro" , Novara , Italy – name: 9 Gastroenterology Unit, Department of Internal Medicine , IRCCS-Ospedale Policlinico San Martino , Genoa , Italy – name: 10 Institute of Histopathology , Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" , Udine , Italy – name: 11 Pathology Department, Barcelona Clinic Liver Cancer (BCLC) Group, Hospital Clínic , University of Barcelona , Barcelona , Spain – name: 14 Department of Surgery and Cancer , Imperial College London , London , UK – name: 3 Department of Infectious Diseases, Faculty of Medicine , Imperial College London, Hammersmith Hospital Campus , London , UK – name: 12 Centre for Pathology , Imperial College London , London , UK – name: 4 Liver Unit, Barcelona Clinic Liver Cancer (BCLC) Group , University of Barcelona, Hospital Clinic , Barcelona , Spain – name: 16 Department of Oncology , University of Milan , Milano , Italy – name: 8 Liver Unit, Hospital Universitari Vall d’Hebron , Universitat Autonoma de Barcelona , Barcelona , Spain – name: 13 Department of Histopathology , University College London Cancer Institute , London , UK – name: 1 Department of Surgery & Cancer, Faculty of Medicine , Imperial College London, Hammersmith Hospital Campus , London , UK – name: 5 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) , Instituto de Salud Carlos III , Madrid , Spain – name: 6 Tokyo Medical and Dental University , Bunkyo-ku , Japan – name: 17 Hepato-Pancreatic-Biliary Surgery and Liver Transplantation , Fondazione IRCCS Istituto Nazionale Tumori , Milan , Italy
Author_xml	– sequence: 1 givenname: David J. orcidid: 0000-0002-3529-0103 surname: Pinato fullname: Pinato, David J. email: david.pinato@imperial.ac.uk organization: Division of Oncology, Department of Translational Medicine, Universita del Piemonte Orientale "A. Avogadro", Novara, Italy – sequence: 2 givenname: Sam M surname: Murray fullname: Murray, Sam M organization: Department of Infectious Diseases, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK – sequence: 3 givenname: Alejandro surname: Forner fullname: Forner, Alejandro organization: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain – sequence: 4 givenname: Takahiro surname: Kaneko fullname: Kaneko, Takahiro organization: Tokyo Medical and Dental University, Bunkyo-ku, Japan – sequence: 5 givenname: Petros orcidid: 0000-0002-7472-8913 surname: Fessas fullname: Fessas, Petros organization: Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK – sequence: 6 givenname: Pierluigi surname: Toniutto fullname: Toniutto, Pierluigi organization: Hepatology and Liver Transplantation Unit, Department of Medical Area (DAME), University of Udine, Udine, Italy – sequence: 7 givenname: Beatriz surname: Mínguez fullname: Mínguez, Beatriz organization: Liver Unit, Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain – sequence: 8 givenname: Valentina surname: Cacciato fullname: Cacciato, Valentina organization: Gastroenterology Unit, Department of Internal Medicine, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy – sequence: 9 givenname: Claudio surname: Avellini fullname: Avellini, Claudio organization: Institute of Histopathology, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia", Udine, Italy – sequence: 10 givenname: Alba surname: Diaz fullname: Diaz, Alba organization: Pathology Department, Barcelona Clinic Liver Cancer (BCLC) Group, Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 11 givenname: Rosemary J. surname: Boyton fullname: Boyton, Rosemary J. organization: Department of Infectious Diseases, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK – sequence: 12 givenname: Daniel M. surname: Altmann fullname: Altmann, Daniel M. organization: Department of Infectious Diseases, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK – sequence: 13 givenname: Robert D surname: Goldin fullname: Goldin, Robert D organization: Centre for Pathology, Imperial College London, London, UK – sequence: 14 givenname: Ayse U surname: Akarca fullname: Akarca, Ayse U organization: Department of Histopathology, University College London Cancer Institute, London, UK – sequence: 15 givenname: Teresa surname: Marafioti fullname: Marafioti, Teresa organization: Department of Histopathology, University College London Cancer Institute, London, UK – sequence: 16 givenname: Francesco A surname: Mauri fullname: Mauri, Francesco A organization: Department of Surgery and Cancer, Imperial College London, London, UK – sequence: 17 givenname: Edoardo surname: Casagrande fullname: Casagrande, Edoardo organization: Gastroenterology Unit, Department of Internal Medicine, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy – sequence: 18 givenname: Federica surname: Grillo fullname: Grillo, Federica organization: Department of Surgical Sciences, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy – sequence: 19 givenname: Edoardo surname: Giannini fullname: Giannini, Edoardo organization: Gastroenterology Unit, Department of Internal Medicine, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy – sequence: 20 givenname: Sherrie surname: Bhoori fullname: Bhoori, Sherrie organization: Hepato-Pancreatic-Biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy – sequence: 21 givenname: Vincenzo surname: Mazzaferro fullname: Mazzaferro, Vincenzo organization: Hepato-Pancreatic-Biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34593621$$D View this record in MEDLINE/PubMed
BookMark	eNp9ks1u1DAUhS1URMvQPSsUiQ0LAraTsR0WSKjip1IlNmVt3Tg3Mx459mAnSOUteGOcyVDaSrCydfOdoxPf85Sc-OCRkOeMvmGsEm93djQlp5yVlFYVY4_IGadrVrKai5M791NyntKOUsoyppR6Qk6ret1UgrMz8us6gk8lxBGjBVeYLQ4BhzY4-xNGG3wBqYDCBRPKiJs8yJD13WQwFqEv7DBMPmzQW1MYdK7oEMZtJoot7mEM82xyEAsD0VgfBniXNXtnzcE9FX2IR5NxixH2N8_I4x5cwvPjuSLfPn28vvhSXn39fHnx4apsc_axbEStBG-aimOPppOtAso64KamPfK-brBTtaKyMQI4hRyrZQhQ1wwaYdBUK3K5-HYBdnof7QDxRgew-jAIcaPzq1jjUEMjKyqEUpLJWjHaGgl9r1jLwahWiuz1fvHaT-2AnUE_RnD3TO9_8XarN-GHzhElZ3U2eHU0iOH7hGnUg03z24HHMCXN11JJWXFWZfTlA3QXppjXMlMq90CITK7Ii7uJbqP82XwG6AKYGFKK2N8ijOq5X3rul577pZd-ZYl4IDF2PKwx_5N1_xO-XoTtsPub9p_4b0Gi5pQ
CitedBy_id	crossref_primary_10_1042_BSR20230634 crossref_primary_10_1007_s12672_025_03362_w crossref_primary_10_1016_j_acra_2024_10_052 crossref_primary_10_2147_OTT_S373631 crossref_primary_10_1007_s00330_023_09919_z crossref_primary_10_4251_wjgo_v16_i7_2888 crossref_primary_10_1136_jitc_2021_004205 crossref_primary_10_1158_1078_0432_CCR_22_3116 crossref_primary_10_1186_s12957_025_03788_0 crossref_primary_10_1186_s41747_025_00563_4 crossref_primary_10_3389_fbinf_2025_1669236 crossref_primary_10_2147_JHC_S487472 crossref_primary_10_1186_s12885_023_11535_5 crossref_primary_10_3892_ol_2024_14398 crossref_primary_10_3748_wjg_v28_i28_3573 crossref_primary_10_1080_13543784_2022_2072726 crossref_primary_10_3389_fimmu_2025_1628571 crossref_primary_10_20517_cdr_2024_212 crossref_primary_10_1097_ot9_0000000000000064 crossref_primary_10_1038_s41598_025_12858_y crossref_primary_10_1038_s41698_024_00693_9 crossref_primary_10_3389_fimmu_2025_1591127 crossref_primary_10_3390_cells11193033 crossref_primary_10_1007_s00432_023_05050_0 crossref_primary_10_4251_wjgo_v17_i6_103198 crossref_primary_10_3389_fonc_2022_982948 crossref_primary_10_3390_biomedicines12092124 crossref_primary_10_1007_s00262_025_04058_4 crossref_primary_10_2147_JHC_S436211 crossref_primary_10_3389_fimmu_2024_1418965 crossref_primary_10_2147_JHC_S399874 crossref_primary_10_1016_j_intimp_2024_114006 crossref_primary_10_2147_JHC_S415843 crossref_primary_10_1016_j_bbcan_2023_188946 crossref_primary_10_2147_JIR_S520339 crossref_primary_10_47717_turkjsurg_2024_6375 crossref_primary_10_1016_j_acra_2024_10_038 crossref_primary_10_1038_s41416_024_02684_w crossref_primary_10_1007_s00261_024_04490_7 crossref_primary_10_1016_j_jconrel_2025_01_088 crossref_primary_10_2217_fon_2022_0916 crossref_primary_10_5582_bst_2023_01275 crossref_primary_10_1007_s00262_024_03857_5 crossref_primary_10_3389_fimmu_2025_1565355 crossref_primary_10_1016_j_clinre_2024_102465 crossref_primary_10_1016_j_jhepr_2025_101555 crossref_primary_10_3390_ijms24108598 crossref_primary_10_3389_fimmu_2025_1577614 crossref_primary_10_1038_s41392_022_01235_0 crossref_primary_10_1007_s00270_024_03813_x crossref_primary_10_1016_j_iliver_2025_100187 crossref_primary_10_1007_s00432_023_05017_1 crossref_primary_10_1007_s12328_024_01921_2 crossref_primary_10_1002_cam4_5841 crossref_primary_10_2147_IJGM_S454421 crossref_primary_10_2147_JHC_S443041 crossref_primary_10_3389_fonc_2022_809860 crossref_primary_10_3390_biology12070999 crossref_primary_10_3390_cancers15205072 crossref_primary_10_3389_fimmu_2023_1205636 crossref_primary_10_1016_S2468_1253_22_00350_8 crossref_primary_10_1007_s00261_024_04709_7 crossref_primary_10_1177_15330338231166765 crossref_primary_10_3389_fonc_2022_954203 crossref_primary_10_1186_s40164_025_00636_5 crossref_primary_10_3389_fonc_2025_1581927 crossref_primary_10_1002_cam4_6302 crossref_primary_10_4251_wjgo_v16_i7_3256 crossref_primary_10_1371_journal_pone_0323829 crossref_primary_10_1007_s00270_024_03724_x crossref_primary_10_4240_wjgs_v16_i9_2829 crossref_primary_10_1080_00365513_2022_2129438 crossref_primary_10_1007_s00330_023_09754_2 crossref_primary_10_1016_j_biomaterials_2024_122480 crossref_primary_10_3389_fimmu_2024_1421520 crossref_primary_10_3748_wjg_v28_i27_3346 crossref_primary_10_1111_liv_16142 crossref_primary_10_1016_j_clinre_2024_102390 crossref_primary_10_1053_j_gastro_2025_03_047 crossref_primary_10_3389_fonc_2022_1054598 crossref_primary_10_2147_JHC_S439001 crossref_primary_10_2147_JHC_S480090 crossref_primary_10_2147_JHC_S417550 crossref_primary_10_1002_jgh3_70163 crossref_primary_10_1186_s12885_024_11936_0 crossref_primary_10_1016_j_lfs_2024_122540 crossref_primary_10_1038_s41420_024_02116_x crossref_primary_10_3389_fimmu_2023_1277329 crossref_primary_10_1136_jitc_2024_010035 crossref_primary_10_2147_JHC_S472286 crossref_primary_10_2169_internalmedicine_5733_25 crossref_primary_10_1007_s00432_023_05231_x crossref_primary_10_3389_fimmu_2025_1573505 crossref_primary_10_1097_HC9_0000000000000548 crossref_primary_10_1148_radiol_232875 crossref_primary_10_1155_2022_2680110 crossref_primary_10_1158_1078_0432_CCR_24_0177 crossref_primary_10_1177_17562848251333295 crossref_primary_10_1007_s00262_025_03962_z crossref_primary_10_1007_s12672_024_00917_1 crossref_primary_10_3389_fonc_2024_1293680 crossref_primary_10_3389_fonc_2022_816198 crossref_primary_10_1016_j_aohep_2025_101905 crossref_primary_10_3389_fimmu_2024_1430571 crossref_primary_10_1016_j_ejrad_2023_111266 crossref_primary_10_2147_JHC_S404500 crossref_primary_10_1016_j_csbj_2024_04_001 crossref_primary_10_1016_j_acra_2023_09_001 crossref_primary_10_1016_j_bbcan_2022_188841 crossref_primary_10_3748_wjg_v30_i8_843 crossref_primary_10_1097_MEG_0000000000002873 crossref_primary_10_3389_fonc_2022_1057560
Cites_doi	10.1053/jhep.2003.50047 10.1159/000506745 10.4049/jimmunol.1900475 10.3390/ijms21072378 10.1002/eji.202048992 10.1111/jgh.13147 10.1006/scbi.1995.0002 10.1016/j.jhep.2013.02.022 10.1002/hep.26731 10.21037/tgh.2017.11.18 10.1111/apt.14066 10.1007/s00280-014-2568-8 10.3748/wjg.v19.i43.7515 10.1038/nrclinonc.2014.122 10.1056/NEJMoa1915745 10.1371/journal.pone.0060444 10.3390/cancers11081085 10.1111/apt.12992 10.1158/2159-8290.CD-17-0256 10.1038/s41586-021-03362-0 10.1016/j.cgh.2014.11.037 10.1158/1078-0432.CCR-17-0950 10.1080/2162402X.2015.1008866 10.2147/JHC.S187121 10.1016/j.jhep.2016.10.029 10.1200/JCO.19.01307 10.1158/0008-5472.CAN-05-2244 10.1136/gutjnl-2019-318934 10.1016/S0140-6736(17)31046-2 10.1007/s10620-007-9986-y 10.1038/s41388-020-1249-9 10.1038/s41571-018-0073-4 10.1016/j.ccell.2019.02.008 10.1093/annonc/mdz394.029 10.1007/s00535-009-0155-2 10.1182/blood-2003-03-0692 10.1016/j.jhep.2016.01.012 10.1038/nri2545 10.1038/bjc.2012.538 10.1016/j.ctrv.2007.04.001 10.1016/S2468-1253(17)30156-5 10.3390/cancers12010212 10.1038/bjc.2013.682 10.1111/cas.14069 10.1038/nrclinonc.2018.29 10.1016/S1470-2045(18)30351-6 10.1158/0008-5472.CAN-11-0268 10.1148/radiol.2015142140 10.1016/j.jhep.2018.03.019
ContentType	Journal Article
Copyright	Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021
Copyright_xml	– notice: Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021
DBID	9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1136/jitc-2021-003311
DatabaseName	BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest One Academic ProQuest One Academic (New) ProQuest - Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	2051-1426
ExternalDocumentID	oai_doaj_org_article_a973066887174810bc7aff81b2ac8b76 PMC8487214 34593621 10_1136_jitc_2021_003311 jitc
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	United Kingdom--UK New York United States--US
GeographicLocations_xml	– name: New York – name: United Kingdom--UK – name: United States--US
GrantInformation_xml	– fundername: Imperial Experimental Cancer Medicine Centre, Cancer Research UK – fundername: Imperial College Healthcare NHS Trust funderid: http://dx.doi.org/10.13039/501100000762 – fundername: Instituto de Salud Carlos III grantid: PI18/00542 funderid: http://dx.doi.org/10.13039/501100004587 – fundername: Cancer Research UK grantid: C57701/A26137 funderid: http://dx.doi.org/10.13039/501100000289 – fundername: Wellcome Trust grantid: PS3416 funderid: http://dx.doi.org/10.13039/100004440 – fundername: Cancer Research UK grantid: C57701/A26137 – fundername: Wellcome Trust grantid: PS3416 – fundername: Wellcome Trust – fundername: Cancer Research UK grantid: 26137 – fundername: ; – fundername: ; grantid: PI18/00542 – fundername: ; grantid: C57701/A26137 – fundername: ; grantid: PS3416
GroupedDBID	4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV ADRAZ AFKRA AHBYD AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR KQ8 M1P M48 M~E OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RMJ RPM RSV SOJ UKHRP AAYXX ADUKV AFFHD AHSBF CITATION EJD H13 ITC PHGZM PJZUB PPXIY ROL CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-b593t-9648629932efecd7b8a01da2c40fe2f49ed848079c6a20adeab1eaa441a96cec3
IEDL.DBID	BENPR
ISICitedReferencesCount	148
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000703191800004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2051-1426
IngestDate	Fri Oct 03 12:53:38 EDT 2025 Tue Nov 04 01:52:04 EST 2025 Fri Sep 05 12:20:13 EDT 2025 Tue Oct 07 06:42:34 EDT 2025 Mon Jul 21 06:03:13 EDT 2025 Sat Nov 29 07:17:09 EST 2025 Tue Nov 18 21:44:58 EST 2025 Thu Apr 24 22:49:47 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	liver neoplasms immunotherapy
Language	English
License	This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-b593t-9648629932efecd7b8a01da2c40fe2f49ed848079c6a20adeab1eaa441a96cec3
Notes	Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-7472-8913 0000-0002-3529-0103
OpenAccessLink	https://www.proquest.com/docview/2583116677?pq-origsite=%requestingapplication%
PMID	34593621
PQID	2583116677
PQPubID	2040222
ParticipantIDs	doaj_primary_oai_doaj_org_article_a973066887174810bc7aff81b2ac8b76 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8487214 proquest_miscellaneous_2578773213 proquest_journals_2583116677 pubmed_primary_34593621 crossref_primary_10_1136_jitc_2021_003311 crossref_citationtrail_10_1136_jitc_2021_003311 bmj_journals_10_1136_jitc_2021_003311
PublicationCentury	2000
PublicationDate	2021-09-01
PublicationDateYYYYMMDD	2021-09-01
PublicationDate_xml	– month: 09 year: 2021 text: 2021-09-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationSeriesTitle	Original research
PublicationTitle	Journal for immunotherapy of cancer
PublicationTitleAbbrev	J Immunother Cancer
PublicationTitleAlternate	J Immunother Cancer
PublicationYear	2021
Publisher	BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group
Publisher_xml	– name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group
References	Finn, Qin, Ikeda (R17) 2020; 382 Facciorusso, Mariani, Sposito (R32) 2016; 31 Bryce, Tsochatzis (R4) 2017; 2 Singh, Toom, Avula (R18) 2020; 7 Pinato, Guerra, Fessas (R11) 2020; 39 Pinato, Vallipuram, Evans (R33) 2021; 111 Flecken, Schmidt, Hild (R38) 2014; 59 Yarchoan, Xing, Luan (R43) 2017; 23 Llovet, Bruix (R1) 2003; 37 Reuben, Gittelman, Gao (R35) 2017; 7 Bellamy, Malcomson, Harrison (R37) 1995; 6 Pinter, Ulbrich, Sieghart (R7) 2015; 277 Yau, Park, Finn (R14) 2019; 30 Green, Ferguson, Zitvogel (R36) 2009; 9 Aversa, Malanga, Fiume (R41) 2020; 21 Zerbini, Pilli, Penna (R21) 2006; 66 Halama, Michel, Kloor (R40) 2011; 71 Kudo, Ueshima, Ikeda (R8) 2020; 69 Dees, Ganesan, Singh (R48) 2021; 51 Pol, Vacchelli, Aranda (R20) 2015; 4 Erhardt, Kolligs, Dollinger (R6) 2014; 74 Hiroishi, Eguchi, Baba (R22) 2010; 45 Meyer, Fox, Ma (R10) 2017; 2 Tampaki, Ionas, Hadziyannis (R19) 2020; 12 Pinato, Howell, Ramaswami (R5) 2017; 45 El-Khoueiry, Sangro, Yau (R13) 2017; 389 Pinato, Arizumi, Allara (R31) 2015; 13 Kriegsman, Vangala, Chen (R42) 2019; 203 Pinato, Karamanakos, Arizumi (R24) 2014; 40 Pfister, Núñez, Pinyol (R39) 2021; 592 Morisco, Stigliano, Godfrey (R30) 2008; 53 Finn, Ryoo, Merle (R16) 2020; 38 Stigliano, Marelli, Yu (R49) 2007; 33 Pinato, Tan, Toussi (R29) 2014; 110 Llovet, Montal, Sia (R50) 2018; 15 Zhu, Finn, Edeline (R15) 2018; 19 Liao, Wang, Huang (R23) 2013; 8 Duffy, Ulahannan, Makorova-Rusher (R45) 2017; 66 Lencioni, Llovet, Han (R9) 2016; 64 Sangro, Gomez-Martin, de la Mata (R12) 2013; 59 Viveiros, Riaz, Lewandowski (R25) 2019; 11 Liao, Overman, Boutin (R44) 2019; 35 Fukumura, Kloepper, Amoozgar (R47) 2018; 15 Ohue, Nishikawa (R46) 2019; 110 Forner, Gilabert, Bruix (R2) 2014; 11 Marafioti, Jones, Facchetti (R34) 2003; 102 (R3) 2018; 69 Pompili, Francica, Ponziani (R26) 2013; 19 Pinato, Ramachandran, Toussi (R27) 2013; 108 Singh (2025100309033051000_9.9.e003311.18) 2020; 7 Morisco (2025100309033051000_9.9.e003311.30) 2008; 53 2025100309033051000_9.9.e003311.35 Pinato (2025100309033051000_9.9.e003311.11) 2020; 39 Tampaki (2025100309033051000_9.9.e003311.19) 2020; 12 2025100309033051000_9.9.e003311.36 2025100309033051000_9.9.e003311.37 2025100309033051000_9.9.e003311.38 2025100309033051000_9.9.e003311.32 Pinter (2025100309033051000_9.9.e003311.7) 2015; 277 2025100309033051000_9.9.e003311.34 Aversa (2025100309033051000_9.9.e003311.41) 2020; 21 Pompili (2025100309033051000_9.9.e003311.26) 2013; 19 Viveiros (2025100309033051000_9.9.e003311.25) 2019; 11 Pinato (2025100309033051000_9.9.e003311.33) 2021; 111 2025100309033051000_9.9.e003311.1 2025100309033051000_9.9.e003311.40 Dees (2025100309033051000_9.9.e003311.48) 2021; 51 2025100309033051000_9.9.e003311.9 2025100309033051000_9.9.e003311.46 2025100309033051000_9.9.e003311.8 2025100309033051000_9.9.e003311.47 2025100309033051000_9.9.e003311.49 2025100309033051000_9.9.e003311.42 2025100309033051000_9.9.e003311.43 2025100309033051000_9.9.e003311.3 2025100309033051000_9.9.e003311.44 2025100309033051000_9.9.e003311.2 Erhardt (2025100309033051000_9.9.e003311.6) 2014; 74 Pinato (2025100309033051000_9.9.e003311.24) 2014; 40 Duffy (2025100309033051000_9.9.e003311.45) 2017; 66 2025100309033051000_9.9.e003311.50 2025100309033051000_9.9.e003311.13 2025100309033051000_9.9.e003311.15 2025100309033051000_9.9.e003311.16 Meyer (2025100309033051000_9.9.e003311.10) 2017; 2 2025100309033051000_9.9.e003311.12 Pfister (2025100309033051000_9.9.e003311.39) 2021; 592 Bryce (2025100309033051000_9.9.e003311.4) 2017; 2 2025100309033051000_9.9.e003311.17 Pinato (2025100309033051000_9.9.e003311.31) 2015; 13 Pinato (2025100309033051000_9.9.e003311.5) 2017; 45 2025100309033051000_9.9.e003311.27 2025100309033051000_9.9.e003311.20 2025100309033051000_9.9.e003311.21 2025100309033051000_9.9.e003311.22 2025100309033051000_9.9.e003311.23 2025100309033051000_9.9.e003311.28 2025100309033051000_9.9.e003311.29 Yau (2025100309033051000_9.9.e003311.14) 2019; 30
References_xml	– volume: 37 start-page: 429 year: 2003 ident: R1 article-title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival publication-title: Hepatology doi: 10.1053/jhep.2003.50047 – volume: 111 start-page: 465 year: 2021 ident: R33 article-title: Programmed cell death ligand expression drives immune Tolerogenesis across the diverse subtypes of neuroendocrine tumours publication-title: Neuroendocrinology doi: 10.1159/000506745 – volume: 203 start-page: 1999 year: 2019 ident: R42 article-title: Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression publication-title: J Immunol doi: 10.4049/jimmunol.1900475 – volume: 21 year: 2020 ident: R41 article-title: Molecular T-cell repertoire analysis as source of prognostic and predictive biomarkers for checkpoint blockade immunotherapy publication-title: Int J Mol Sci doi: 10.3390/ijms21072378 – volume: 51 start-page: 280 year: 2021 ident: R48 article-title: Regulatory T cell targeting in cancer: emerging strategies in immunotherapy publication-title: Eur J Immunol doi: 10.1002/eji.202048992 – volume: 31 start-page: 645 year: 2016 ident: R32 article-title: Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13147 – volume: 6 start-page: 3 year: 1995 ident: R37 article-title: Cell death in health and disease: the biology and regulation of apoptosis publication-title: Semin Cancer Biol doi: 10.1006/scbi.1995.0002 – volume: 59 start-page: 81 year: 2013 ident: R12 article-title: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C publication-title: J Hepatol doi: 10.1016/j.jhep.2013.02.022 – volume: 59 start-page: 1415 year: 2014 ident: R38 article-title: Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.26731 – volume: 2 year: 2017 ident: R4 article-title: Downstaging for hepatocellular cancer: harm or benefit? publication-title: Transl Gastroenterol Hepatol doi: 10.21037/tgh.2017.11.18 – volume: 45 start-page: 1514 year: 2017 ident: R5 article-title: Review article: delivering precision oncology in intermediate-stage liver cancer publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14066 – volume: 74 start-page: 947 year: 2014 ident: R6 article-title: TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2568-8 – volume: 19 start-page: 7515 year: 2013 ident: R26 article-title: Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation publication-title: World J Gastroenterol doi: 10.3748/wjg.v19.i43.7515 – volume: 11 start-page: 525 year: 2014 ident: R2 article-title: Treatment of intermediate-stage hepatocellular carcinoma publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2014.122 – volume: 382 start-page: 1894 year: 2020 ident: R17 article-title: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1915745 – volume: 8 year: 2013 ident: R23 article-title: Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study publication-title: PLoS One doi: 10.1371/journal.pone.0060444 – volume: 11 year: 2019 ident: R25 article-title: Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC) publication-title: Cancers doi: 10.3390/cancers11081085 – volume: 40 start-page: 1270 year: 2014 ident: R24 article-title: Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12992 – volume: 7 start-page: 1088 year: 2017 ident: R35 article-title: Tcr repertoire Intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0256 – volume: 592 start-page: 450 year: 2021 ident: R39 article-title: NASH limits anti-tumour surveillance in immunotherapy-treated HCC publication-title: Nature doi: 10.1038/s41586-021-03362-0 – volume: 13 start-page: 1204 year: 2015 ident: R31 article-title: Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.11.037 – volume: 23 start-page: 7333 year: 2017 ident: R43 article-title: Characterization of the immune microenvironment in hepatocellular carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0950 – volume: 4 year: 2015 ident: R20 article-title: Trial Watch: immunogenic cell death inducers for anticancer chemotherapy publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1008866 – volume: 69 start-page: 182 year: 2018 ident: R3 article-title: Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol – volume: 7 start-page: 11 year: 2020 ident: R18 article-title: The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma publication-title: J Hepatocell Carcinoma doi: 10.2147/JHC.S187121 – volume: 66 start-page: 545 year: 2017 ident: R45 article-title: Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2016.10.029 – volume: 38 start-page: 193 year: 2020 ident: R16 article-title: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.19.01307 – volume: 66 start-page: 1139 year: 2006 ident: R21 article-title: Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2244 – volume: 69 start-page: 1492 year: 2020 ident: R8 article-title: Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial publication-title: Gut doi: 10.1136/gutjnl-2019-318934 – volume: 389 start-page: 2492 year: 2017 ident: R13 article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial publication-title: Lancet doi: 10.1016/S0140-6736(17)31046-2 – volume: 53 start-page: 1131 year: 2008 ident: R30 article-title: Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients publication-title: Dig Dis Sci doi: 10.1007/s10620-007-9986-y – volume: 39 start-page: 3620 year: 2020 ident: R11 article-title: Immune-based therapies for hepatocellular carcinoma publication-title: Oncogene doi: 10.1038/s41388-020-1249-9 – volume: 15 start-page: 599 year: 2018 ident: R50 article-title: Molecular therapies and precision medicine for hepatocellular carcinoma publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-018-0073-4 – volume: 35 start-page: 559 year: 2019 ident: R44 article-title: KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.02.008 – volume: 30 start-page: v874 year: 2019 ident: R14 article-title: CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (PTS) with advanced hepatocellular carcinoma (aHCC) publication-title: Annals of Oncology doi: 10.1093/annonc/mdz394.029 – volume: 45 start-page: 451 year: 2010 ident: R22 article-title: Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma publication-title: J Gastroenterol doi: 10.1007/s00535-009-0155-2 – volume: 102 start-page: 2868 year: 2003 ident: R34 article-title: Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology publication-title: Blood doi: 10.1182/blood-2003-03-0692 – volume: 64 start-page: 1090 year: 2016 ident: R9 article-title: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the space trial publication-title: J Hepatol doi: 10.1016/j.jhep.2016.01.012 – volume: 9 start-page: 353 year: 2009 ident: R36 article-title: Immunogenic and tolerogenic cell death publication-title: Nat Rev Immunol doi: 10.1038/nri2545 – volume: 108 start-page: 429 year: 2013 ident: R27 article-title: Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations publication-title: Br J Cancer doi: 10.1038/bjc.2012.538 – volume: 33 start-page: 437 year: 2007 ident: R49 article-title: Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2007.04.001 – volume: 2 start-page: 565 year: 2017 ident: R10 article-title: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(17)30156-5 – volume: 12 year: 2020 ident: R19 article-title: Association of Tim-3 with BCLC stage, serum PD-L1 detection, and response to transarterial chemoembolization in patients with hepatocellular carcinoma publication-title: Cancers doi: 10.3390/cancers12010212 – volume: 110 start-page: 115 year: 2014 ident: R29 article-title: An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes publication-title: Br J Cancer doi: 10.1038/bjc.2013.682 – volume: 110 start-page: 2080 year: 2019 ident: R46 article-title: Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? publication-title: Cancer Sci doi: 10.1111/cas.14069 – volume: 15 start-page: 325 year: 2018 ident: R47 article-title: Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2018.29 – volume: 19 start-page: 940 year: 2018 ident: R15 article-title: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30351-6 – volume: 71 start-page: 5670 year: 2011 ident: R40 article-title: Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-0268 – volume: 277 start-page: 903 year: 2015 ident: R7 article-title: Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo publication-title: Radiology doi: 10.1148/radiol.2015142140 – ident: 2025100309033051000_9.9.e003311.17 doi: 10.1056/NEJMoa1915745 – ident: 2025100309033051000_9.9.e003311.23 doi: 10.1371/journal.pone.0060444 – ident: 2025100309033051000_9.9.e003311.27 doi: 10.1038/bjc.2012.538 – volume: 11 year: 2019 ident: 2025100309033051000_9.9.e003311.25 article-title: Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC) publication-title: Cancers doi: 10.3390/cancers11081085 – volume: 45 start-page: 1514 year: 2017 ident: 2025100309033051000_9.9.e003311.5 article-title: Review article: delivering precision oncology in intermediate-stage liver cancer publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14066 – ident: 2025100309033051000_9.9.e003311.49 doi: 10.1016/j.ctrv.2007.04.001 – ident: 2025100309033051000_9.9.e003311.21 doi: 10.1158/0008-5472.CAN-05-2244 – volume: 111 start-page: 465 year: 2021 ident: 2025100309033051000_9.9.e003311.33 article-title: Programmed cell death ligand expression drives immune Tolerogenesis across the diverse subtypes of neuroendocrine tumours publication-title: Neuroendocrinology doi: 10.1159/000506745 – ident: 2025100309033051000_9.9.e003311.37 doi: 10.1006/scbi.1995.0002 – ident: 2025100309033051000_9.9.e003311.32 doi: 10.1111/jgh.13147 – ident: 2025100309033051000_9.9.e003311.12 doi: 10.1016/j.jhep.2013.02.022 – ident: 2025100309033051000_9.9.e003311.36 doi: 10.1038/nri2545 – volume: 592 start-page: 450 year: 2021 ident: 2025100309033051000_9.9.e003311.39 article-title: NASH limits anti-tumour surveillance in immunotherapy-treated HCC publication-title: Nature doi: 10.1038/s41586-021-03362-0 – volume: 51 start-page: 280 year: 2021 ident: 2025100309033051000_9.9.e003311.48 article-title: Regulatory T cell targeting in cancer: emerging strategies in immunotherapy publication-title: Eur J Immunol doi: 10.1002/eji.202048992 – volume: 66 start-page: 545 year: 2017 ident: 2025100309033051000_9.9.e003311.45 article-title: Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2016.10.029 – volume: 2 year: 2017 ident: 2025100309033051000_9.9.e003311.4 article-title: Downstaging for hepatocellular cancer: harm or benefit? publication-title: Transl Gastroenterol Hepatol doi: 10.21037/tgh.2017.11.18 – ident: 2025100309033051000_9.9.e003311.13 doi: 10.1016/S0140-6736(17)31046-2 – volume: 40 start-page: 1270 year: 2014 ident: 2025100309033051000_9.9.e003311.24 article-title: Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12992 – volume: 53 start-page: 1131 year: 2008 ident: 2025100309033051000_9.9.e003311.30 article-title: Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients publication-title: Dig Dis Sci doi: 10.1007/s10620-007-9986-y – ident: 2025100309033051000_9.9.e003311.28 – ident: 2025100309033051000_9.9.e003311.43 doi: 10.1158/1078-0432.CCR-17-0950 – volume: 2 start-page: 565 year: 2017 ident: 2025100309033051000_9.9.e003311.10 article-title: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(17)30156-5 – ident: 2025100309033051000_9.9.e003311.15 doi: 10.1016/S1470-2045(18)30351-6 – ident: 2025100309033051000_9.9.e003311.29 doi: 10.1038/bjc.2013.682 – volume: 12 year: 2020 ident: 2025100309033051000_9.9.e003311.19 article-title: Association of Tim-3 with BCLC stage, serum PD-L1 detection, and response to transarterial chemoembolization in patients with hepatocellular carcinoma publication-title: Cancers doi: 10.3390/cancers12010212 – volume: 277 start-page: 903 year: 2015 ident: 2025100309033051000_9.9.e003311.7 article-title: Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo publication-title: Radiology doi: 10.1148/radiol.2015142140 – ident: 2025100309033051000_9.9.e003311.35 doi: 10.1158/2159-8290.CD-17-0256 – volume: 74 start-page: 947 year: 2014 ident: 2025100309033051000_9.9.e003311.6 article-title: TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2568-8 – ident: 2025100309033051000_9.9.e003311.34 doi: 10.1182/blood-2003-03-0692 – ident: 2025100309033051000_9.9.e003311.44 doi: 10.1016/j.ccell.2019.02.008 – volume: 13 start-page: 1204 year: 2015 ident: 2025100309033051000_9.9.e003311.31 article-title: Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.11.037 – volume: 39 start-page: 3620 year: 2020 ident: 2025100309033051000_9.9.e003311.11 article-title: Immune-based therapies for hepatocellular carcinoma publication-title: Oncogene doi: 10.1038/s41388-020-1249-9 – volume: 19 start-page: 7515 year: 2013 ident: 2025100309033051000_9.9.e003311.26 article-title: Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation publication-title: World J Gastroenterol doi: 10.3748/wjg.v19.i43.7515 – ident: 2025100309033051000_9.9.e003311.47 doi: 10.1038/nrclinonc.2018.29 – volume: 21 year: 2020 ident: 2025100309033051000_9.9.e003311.41 article-title: Molecular T-cell repertoire analysis as source of prognostic and predictive biomarkers for checkpoint blockade immunotherapy publication-title: Int J Mol Sci doi: 10.3390/ijms21072378 – ident: 2025100309033051000_9.9.e003311.9 doi: 10.1016/j.jhep.2016.01.012 – ident: 2025100309033051000_9.9.e003311.20 doi: 10.1080/2162402X.2015.1008866 – volume: 7 start-page: 11 year: 2020 ident: 2025100309033051000_9.9.e003311.18 article-title: The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma publication-title: J Hepatocell Carcinoma doi: 10.2147/JHC.S187121 – ident: 2025100309033051000_9.9.e003311.8 doi: 10.1136/gutjnl-2019-318934 – volume: 30 start-page: v874 year: 2019 ident: 2025100309033051000_9.9.e003311.14 article-title: CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (PTS) with advanced hepatocellular carcinoma (aHCC) publication-title: Annals of Oncology doi: 10.1093/annonc/mdz394.029 – ident: 2025100309033051000_9.9.e003311.3 doi: 10.1016/j.jhep.2018.03.019 – ident: 2025100309033051000_9.9.e003311.38 doi: 10.1002/hep.26731 – ident: 2025100309033051000_9.9.e003311.46 doi: 10.1111/cas.14069 – ident: 2025100309033051000_9.9.e003311.1 doi: 10.1053/jhep.2003.50047 – ident: 2025100309033051000_9.9.e003311.16 doi: 10.1200/JCO.19.01307 – ident: 2025100309033051000_9.9.e003311.40 doi: 10.1158/0008-5472.CAN-11-0268 – ident: 2025100309033051000_9.9.e003311.42 doi: 10.4049/jimmunol.1900475 – ident: 2025100309033051000_9.9.e003311.2 doi: 10.1038/nrclinonc.2014.122 – ident: 2025100309033051000_9.9.e003311.22 doi: 10.1007/s00535-009-0155-2 – ident: 2025100309033051000_9.9.e003311.50 doi: 10.1038/s41571-018-0073-4
SSID	ssj0001033888
Score	2.565273
Snippet	BackgroundModulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell... Modulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function...
SourceID	doaj pubmedcentral proquest pubmed crossref bmj
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	e003311
SubjectTerms	Adult Aged Apoptosis Cancer Cancer therapies Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Cell death Chemoembolization Chemoembolization, Therapeutic - methods Chemotherapy Clinical trials Clinical/Translational Cancer Immunotherapy Cytotoxicity Embolization Female Gene expression Humans Immunogenic Cell Death - drug effects Immunotherapy Immunotherapy - methods Ligands Liver cancer liver neoplasms Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Middle Aged Patients Surgery Tumors
SummonAdditionalLinks	– databaseName: DOAJ: Directory of Open Access Journal (DOAJ) dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4s1CQUaCA4doN3biBzdAVByg4gBSb5HtOGqqboJ2UyR-Bv-Yb5zsdhehcuHql8aZbzIz9niGsZc5na15U2cF5b8s6sZkrml8pq0urc-jtT7lmf2kj4_NyYn9slPqi2LCxvTA44ebOwsMKgVZgO1s8oUPGovB2BIuGK9Tsm1YPTvOVDpdWcD1MmZzLynV_KwdAiAh4DyjjwoGXffLsz1tlJL2_83S_DNgckcDHd1htyfTkb8dSb7LrsXuHrv5ebocv89-Jb2TpSBNoIqDHcs-Ln1_Pr215G7NHYf26jOqx0A2OIdLDuaueN_wlp6K9ABUGzid5_OazEOM4KfQWUNPbRS0ygPVH-r6pXuDOZf33xz277TI-Krr5wP27ejD1_cfs6niQuZLK4fMqgIeDkwWEZsYau2NW-S1E6FYNFE0hY21oTfoNignFg5kgJ3OwaRyVoUY5EN20PVdfMy40EKiMReqlMBB9OSchNqVstY1fgMz9grfv5okZl0lZ0SqivhUEZ-qkU8zNt9wqApT2nKqnnF-xYzX2xnfx5QdV4x9R0zfjqNk26kBEKwmCFb_guCMHW4gc7kfURqsr5TGTl9suyG7xCzXxf6CxuB3qaXI5Yw9GhG2pUQWVGtRgEK9h709Uvd7uvY05QcHi-DXF0_-x96esluj0FBU3SE7GFYX8Rm7EX4M7Xr1PAndb-VpMpY priority: 102 providerName: Directory of Open Access Journals
Title	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy
URI	https://jitc.bmj.com/content/9/9/e003311.full https://www.ncbi.nlm.nih.gov/pubmed/34593621 https://www.proquest.com/docview/2583116677 https://www.proquest.com/docview/2578773213 https://pubmed.ncbi.nlm.nih.gov/PMC8487214 https://doaj.org/article/a973066887174810bc7aff81b2ac8b76
Volume	9
WOSCitedRecordID	wos000703191800004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RBZ dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: 7X7 dateStart: 20130501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: BENPR dateStart: 20130501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: PIMPY dateStart: 20130501 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZoFyEuvB-FpTISHDhEbezEDy6IRbsCia0qBFI5RbbjsFlt46XtIvEz-MfMJG5LEeqFS6T4EU00n-dle4aQFynG1qwqkwzzX2ZlpRJTVTaRWubapl5r2-aZ_SgnEzWb6WkMuC3jscq1TGwFdRkcxshHLFc8TYWQ8s3l9wSrRuHuaiyh0SMHmKks65ODo-PJ9NM2yjIGF0yp9f4kF6PzeuUAGgycaOjDwkE9Oz_f0Upt8v5_WZx_H5z8QxOd3P7ff7hDbkUblL7tQHOXXPPNPXLjNO6y3ye_WgWWtKc9AZ4U-DoPfm7DRby0Sc2SGgpqMCRY2AGNeQq-PaBkQUNFa7xzEgCZtaO4MUBLtDNhBD0D5bcK2IanX6nDQkZNmJvXMGe7kU7BkI4f6a6H_XxAvpwcf373PomlGxKba75KtMjAVQLbh_nKu1JaZcZpaZjLxpVnVaZ9qfAyu3bCsLEBMgAXxoBtZrRw3vGHpN-Exj8mlEnGoTFlIucAKG_Ry3GlyXkpS5AnA_ISGFjEpbcsWq-GiwIZXSCji47RAzJas7hwMf85luG42DPj1WbGZZf7Y8_YI0TNZhxm7W4bwuJbEYVAYTTIUyFAroMfqNKxdRIWBjgOzDhlpRiQwzVutv-zBc2APN90gxBAZpnGhyscA3JXcpbyAXnUQXRDCc-waCMDCuUOeHdI3e1p6rM20TiwSLI0e7KfrKfkZree8ODdIemvFlf-Gbnufqzq5WJIenIm26caxtU5bAMf8Db9cDr9-hvSmUcS
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB61KQIuvCmBAkaiBw6rZO3NehcJIV5VoyZRDkUqp8Vre9utmnVJUlB_Bn-E38jMPhKCUG49cPVjNWt_M-Ox5wHw0qe7tTQyXkD5LwOTRZ7KstSTsezFqW_jOC3zzA7kaBQdHcXjDfjVxMKQW2UjE0tBbZymO_IO70XC98NQyrfn3zyqGkWvq00JjQoWB_byB5psszf9j7i_u5zvfTr8sO_VVQW8tBeLuReHAZ7iUS1zm1ltZBqprm8U10E3szwLYmsiirOOdah4VxmrkGSl8Nig4lBbLfC7m7AVINijFmyN-8Pxl-WtThdNvihq3kNF2DnN5xqhyNFoxz4qVLSZTk5XtGBZLOBfJ9y_HTX_0Hx7t_-3NbsDt-ozNntXMcVd2LDFPbg-rL0I7sPPUkF7pTcrsh9D3E6cnaTurA5KZWrGFEM17zwqXEHGCssLg1wwZS5jOcXUOOS8XDN6-GCGztE4gp2gcp87aiPvXqapUFPhJuo1zlk6CjA0FOqPVOFvlw_g85UsyENoFa6wj4BxyQU2-jzsCWQYm5IVp43qCSMNyss27CJgklq0zJLSahNhQsBKCFhJBaw2dBpIJbrO705lRs7WzHi1mHFe5TZZM_Y9oXQxjrKSlw1uepzUQi5RMeqLMES9hXZu5HdTLZHx0TDiSkepDNuw0-B0-T9LkLbhxaIbhRxtliqsu6AxqFek4L5ow3bFEgtKREBFKTlSKFeYZYXU1Z4iPykTqeMWSe4Hj9eT9Rxu7B8OB8mgPzp4AjcrXiYnwx1ozacX9ilc09_n-Wz6rJYGDL5eNTP9BnRwokQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELbaFFVceD8CBYxEDxxW2bU39i4SQkCJiNpGOYBUTlu_lm7VrEuSgvoz-Dv8Omb2kRCEcuuBqx-rWfubGY89D0JeRHi3phMbxJj_MrZ5Eqg814FMZT_VkUtTXeWZPZCjUXJ0lI43yK82FgbdKluZWAlq6w3ekfdYP-FRJISUvbxxixjvDd6cfwuwghS-tLblNGqI7LvLH2C-zV4P92CvdxkbfPj0_mPQVBgIdD_l8yAVMZzoQUUzlztjpU5UGFnFTBzmjuVx6myCMdepEYqFyjoF5CsFRwiVCuMMh-9uki2JP9ohW-Ph4fjL8oYnBPMvSdq3US56p8XcACwZGPDQh0WLNvXkdEUjVoUD_nXa_dtp8w8tOLj5P6_fLXKjOXvTtzWz3CYbrrxDtg8b74K75GeluIPKyxXYkgKeJ95NtD9rglWpmlFFQf37AAtaoBFDi9ICd0ypz2mBsTYeOLIwFB9EqMXzNYygJ6D05x7b0OuXGizgVPqJegVzlg4EFAyI5iN1WNzlPfL5ShbkPumUvnQPCWWScWiMmOhzwJfTaN0Zq_rcSgtytEt2ATxZI3JmWWXNcZEhyDIEWVaDrEt6Lbwy0-R9x_IjZ2tmvFzMOK9znqwZ-w4RuxiH2cqrBj_9mjXCL1Mp6BEhQJ-B_ZtEoTYSBAIYTEyZREvRJTstZpf_swRslzxfdIPww81SpfMXOAb0jeQs4l3yoGaPBSU8xmKVDCiUK4yzQupqT1mcVAnWYYski-JH68l6RraBg7KD4Wj_MbleszX6Hu6Qznx64Z6Qa-b7vJhNnzaCgZLjq-al3xGgqwQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trans-arterial+chemoembolization+as+a+loco-regional+inducer+of+immunogenic+cell+death+in+hepatocellular+carcinoma%3A+implications+for+immunotherapy&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Pinato%2C+David+J.&rft.au=Murray%2C+Sam+M&rft.au=Forner%2C+Alejandro&rft.au=Kaneko%2C+Takahiro&rft.date=2021-09-01&rft.issn=2051-1426&rft.eissn=2051-1426&rft.volume=9&rft.issue=9&rft.spage=e003311&rft_id=info:doi/10.1136%2Fjitc-2021-003311&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_jitc_2021_003311
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon